Abstract: The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Abstract: An assembly (10) for introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle, has a feed connector (14) which opens into the exhaust pipe (12) and includes a wall (16), a feed device (20) for reducing agents which opens into the feed connector (14), and a device (22) for generating a gas flow (G) which is additional to the reducing agent flow (R) and lines the wall (16) of the feed 10 connector (14). Furthermore, there is described a method of introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle.

Abstract: An assembly (10) for introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle, has a feed connector (14) which opens into the exhaust pipe (12) and includes a wall (16), a feed device (20) for reducing agents which opens into the feed connector (14), and a device (22) for generating a gas flow (G) which is additional to the reducing agent flow (R) and lines the wall (16) of the feed 10 connector (14). Furthermore, there is described a method of introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle.

Abstract: An assembly (10) for introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle, has a feed connector (14) which opens into the exhaust pipe (12) and includes a wall (16), a feed device (20) for reducing agents which opens into the feed connector (14), and a device (22) for generating a gas flow (G) which is additional to the reducing agent flow (R) and lines the wall (16) of the feed 10 connector (14). Furthermore, there is described a method of introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle.

Abstract: An assembly (10) for introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle, has a feed connector (14) which opens into the exhaust pipe (12) and includes a wall (16), a feed device (20) for reducing agents which opens into the feed connector (14), and a device (22) for generating a gas flow (G) which is additional to the reducing agent flow (R) and lines the wall (16) of the feed 10 connector (14). Furthermore, there is described a method of introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle.

Abstract: The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Abstract: An assembly (10) for introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle, has a feed connector (14) which opens into the exhaust pipe (12) and includes a wall (16), a feed device (20) for reducing agents which opens into the feed connector (14), and a device (22) for generating a gas flow (G) which is additional to the reducing agent flow (R) and lines the wall (16) of the feed 10 connector (14). Furthermore, there is described a method of introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle.

Abstract: An assembly (10) for introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle, has a feed connector (14) which opens into the exhaust pipe (12) and includes a wall (16), a feed device (20) for reducing agents which opens into the feed connector (14), and a device (22) for generating a gas flow (G) which is additional to the reducing agent flow (R) and lines the wall (16) of the feed 10 connector (14). Furthermore, there is described a method of introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle.

Abstract: An assembly (10) for introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle, has a feed connector (14) which opens into the exhaust pipe (12) and includes a wall (16), a feed device (20) for reducing agents which opens into the feed connector (14), and a device (22) for generating a gas flow (G) which is additional to the reducing agent flow (R) and lines the wall (16) of the feed 10 connector (14). Furthermore, there is described a method of introducing a reducing agent into the exhaust pipe (12) of an exhaust system of an internal combustion engine, in particular of a motor vehicle.

Abstract: The present invention relates to a beneficial treatment of tumours in patients suffering from NSCLC, and to a clinical marker useful as predictive variable of the responsiveness of tumours in patients suffering from NSCLC. The present invention further relates to a method for selecting patients likely to respond to a given therapy, wherein said method optionally comprises the use of a specific clinical marker. The present invention further relates to a method for delaying disease progression and/or prolonging patient survival of NSCLC patients, wherein said method comprises the use of a specific clinical marker.

Abstract: The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Abstract: A mixing element has a grid which includes a plurality of rows parallel to each other and a plurality of deflector elements which project from the grid and are inclined in relation to the grid plane normal. All deflector elements of one row are inclined in the same direction. The deflector elements of at least two immediately adjacent first rows are inclined in the same direction. The mixing element is used in an exhaust system of an internal combustion engine.

Abstract: The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Abstract: A static mixing element, in particular for arrangement in an exhaust system of an internal combustion engine, has a grid-like component having a flow therethrough. The grid-like component is formed in one piece from an elongated metal strip. In the production of the static mixing element, the metal strip is bent to form the grid-like component.

Abstract: The present invention relates to a pharmaceutical combination which may be useful for the treatment of diseases which involve cell proliferation, which involve migration or apoptosis of myeloma cells, which involve angiogenesis or which involve fibrosis. The invention also relates to a method for the treatment of said diseases, comprising simultaneous, separate or sequential administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

Abstract: The present invention relates generally to the field of Hepatitis B variants exhibiting a reduced sensitivity to nucleoside analogues both in vivo and in vitro. More in particular, reverse transcriptase mutant rt I233V is provided. Present invention provides assays and methods for detecting such variant, which assays are useful in monitoring anti-viral therapeutic regimes and adjusting patient therapy. A diagnostic kit for detecting the presence of an HBV variant in a biological sample has also been described. Finally, the use of a pharmaceutical composition to cure a subject suffering from a HBV infection, which HBV is resistant to lamuvidine and/or adefovir has been provided, which pharmaceutical composition comprises the nucleoside analogue tenofovir.

Abstract: A static mixing element, in particular for arrangement in an exhaust system of an internal combustion engine, has a grid-like component having a flow therethrough. The grid-like component is formed in one piece from an elongated metal strip. In the production of the static mixing element, the metal strip is bent to form the grid-like component.

Abstract: An assembly and method for introducing a reducing agent into an exhaust pipe of an exhaust system of an internal combustion engine, in particular of a motor vehicle includes a feed connector which opens into the exhaust pipe and has a wall; a feed device for reducing agents which opens into the feed connector; and a device that generates a gas flow which is additional to the reducing agent flow and lines the wall of the feed connector.

Abstract: A mixing element has a grid which includes a plurality of rows parallel to each other and a plurality of deflector elements which project from the grid and are inclined in relation to the grid plane normal. All deflector elements of one row are inclined in the same direction. The deflector elements of at least two immediately adjacent first rows are inclined in the same direction. The mixing element is used in an exhaust system of an internal combustion engine.

Abstract: A system and methods for the automatic transmission of new, high affinity media to a user are provided. In connection with a system that convergently merges perceptual and digital signal processing analysis of media entities for purposes of classifying the media entities, various means are provided to a user for automatically extracting media entities that represent a high (or low) affinity state/space for the user in connection with the generation of a high affinity playlist, channel or station. Techniques for providing a dynamic recommendation engine and techniques for rating media entities are also included are also included. Once a high affinity state/space is identified, the high affinity state/space may be persisted for the user from experience to experience.